Wockhardt share news and announcements
NSE: WOCKPHARMABSE: 532300Pharmaceuticals & BiotechnologySmall Cap
Last close ₹1,801.70down ₹53.80 (2.90%)BSE ₹1,801.25
Share price at the NSE close on 23 Oct 2026. Previous close ₹1,855.50.
52-week range of traded prices to 23 Oct 2026
₹1,086.70Low, 23 Mar 2026₹2,422.30High, 1 Jun 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹29,276 Cr311th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
- 71.6
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet.
- 5.9
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 8.8%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 7.4%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.40
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 8,79,19043.6% delivered
Wockhardt share news and announcements
1,008 announcements, routine notices left out, newest first. Page 17 of 21.
Aug 2011
9 Aug · Results
Standalone Results for the quarter ended on 30-JUN-2011 as follows: Net Sales of Rs. 55085 lacs for quarter ending on 30-JUN-2011 against Rs. 39977 lacs for the quarter ending on 30-JUN-2010. Net Profit / (Loss) of Rs. 8268 lacs for the quarter ending on 30-JUN-2011 against Rs. (16314) lacs for the quarter ending on 30-JUN-2010.9 Aug · Results
Consolidated Results for the quarter ended on 30-JUN-2011 as follows: Net Sales of Rs. 105321 lacs for quarter ending on 30-JUN-2011 against Rs. 92164 lacs for the quarter ending on 30-JUN-2010. Net Profit / (Loss) of Rs. 19396 lacs for the quarter ending on 30-JUN-2011 against Rs. (11628) lacs for the quarter ending on 30-JUN-2010.
Jul 2011
28 Jul · Board meeting
Inter alia, to consider and approve the unaudited financial results of the Company for the quarter ended June 30, 2011.13 Jul · Legal
Spurt in Volume : Substantial increase in trading volumes have been observed in Wockhardt Limited.The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Wockhardt Limited has vide its letter inter-alia stated," We would like to inform that the company has been disseminating the price sensitive information on a regular and timely basis to the exchanges, as and when any event occurs to ensure that the investors have latest relevant information and presently, we have no additional information."
Jun 2011
May 2011
19 May · Change in Company Secretary
Mr. Vijay Khetan has been appointed as Company Secretary of the Company w.e.f. May 19, 2011 and Mr. Jayant Manmadkar has resigned from the position of Company Secretary of the Company w.e.f. May 19, 2011.19 May · Results
Standalone Results for the year ended on 31-MAR-2011 as follows: Net Sales of Rs. 175492 lacs for year ending on 31-MAR-2011. Net Profit / (Loss) of Rs. (13207) lacs for the year ending on 31-MAR-2011.19 May · Results
Consolidated Results for the year ended on 31-MAR-2011 as follows: Net Sales of Rs. 375124 lacs for year ending on 31-MAR-2011. Net Profit / (Loss) of Rs. 9052 lacs for the year ending on 31-MAR-2011.10 May · Board meeting
Inter alia, to transact the following business : (1) To consider and approve the audited Standalone and Consolidated Financial Accounts of the Company for the year ended March 31, 2011; (2) To consider and approve the audited Financial Results of the Company for the quarter and year ended March 31, 2011.5 May · Business
Hon'ble High Court of Delhi has approved the Scheme of Arrangement under Section 391 to 394 of the Companies Act, 1956 in the nature of Demerger of Nutrition business of Vinton Healthcare Limited, a wholly owned subsidiary of the Company into Wockhardt Limited ("the Company") with effect from the appointed date i.e. January 01, 2011.
Apr 2011
27 Apr · Results
Company will submit Audited Financial Results for the Financial Year ended March 31, 2011 on or before May 30, 2011 and hence the unaudited financial results for the last quarter ended March 31, 2011 will not be submitted to the Exchange.
Mar 2011
23 Mar · Updates
Division Bench of the Hon'ble Bombay High Court, on March 23, 2011, granted ad-interim relief by staying the admission of the winding up Petition filed by the Trustees to the Foreign Currency Convertible Bonds, issued by the Company. In the meantime the Company has agreed to deposit in Court Rs. 115 crores by May 03, 2011, as per direction of the Hon'ble Bombay High Court.14 Mar · Updates
Hon'ble Bombay high Court has admitted a petition for winding-up of the Company, filed by the Trustees to the Foreign Currency Convertible Bonds issued by the Company. However, there is no winding up order against the Company. In the Meanwhile, the Company has decided to file an appeal against the order and the Petition itself and seek stay of the admission.
Feb 2011
2 Feb · Management
At the meeting of the Board of Directors of the Company held on February 02, 2011, the Audit Committee approved and the Board noted appointment of Mr. S. Giridhar as Chief Financial Officer (CFO) of the Company designated as "President - Finance" w.e.f. November 24, 2010.2 Feb · Results
Consolidated Results for the quarter ended on 31-DEC-2010 as follows: Net Sales of Rs. 95080 lacs for quarter ending on 31-DEC-2010 against Rs. 88933 lacs for the quarter ending on 31-DEC-2009. Net Profit / (Loss) of Rs. 14167 lacs for the quarter ending on 31-DEC-2010 against Rs. (18123) lacs for the quarter ending on 31-DEC-2009.2 Feb · Results
Standalone Results for the quarter ended on 31-DEC-2010 as follows: Net Sales of Rs. 45670 lacs for quarter ending on 31-DEC-2010 against Rs. 39544 lacs for the quarter ending on 31-DEC-2009. Net Profit / (Loss) of Rs. 6668 lacs for the quarter ending on 31-DEC-2010 against Rs. (15996) lacs for the quarter ending on 31-DEC-2009.
Jan 2011
19 Jan · Board meeting
Inter alia, to consider and approve the unaudited financial results of the Company for the quarter and nine months ended December 31, 2010.12 Jan · Business
Board of Directors of the Company at their meeting held on January 12, 2011 have considered and approved Scheme of Arrangement under Section 391 to 394 of the Companies Act, 1956 in the nature of Demerger of Nutrition business of the Vinton Healthcare Limited, a wholly owned subsidiary of the Company into Wockhardt Limited ("the Company") with effect from the appointed date January 1, 2011. As Vinton Healthcare Limited is a wholly owned subsidiary of the Company, no shares would be issued by the Company pursuant to the aforesaid Scheme of Demerger. The said scheme of Arrangement in the nature of Demerger shall be subject to the approval of shareholders of the Vinton Healthcare Limited ("Demerged Company"), the approval of Jurisdictional High Court in which Demerged Company is situated and requisite consent and approval of the statutory and regulatory authorities as may be required for the implementation of the scheme.
Nov 2010
12 Nov · Results
Consolidated Results for the quarter ended on 30-SEP-2010 as follows: Net Sales of Rs. 94007 lacs for quarter ending on 30-SEP-2010 against Rs. 92269 lacs for the quarter ending on 30-SEP-2009. Net Profit / (Loss) of Rs. (9668) lacs for the quarter ending on 30-SEP-2010 against Rs. (5420) lacs for the quarter ending on 30-SEP-2009.12 Nov · Results
Standalone Results for the quarter ended on 30-SEP-2010 as follows: Net Sales of Rs. 47510 lacs for quarter ending on 30-SEP-2010 against Rs. 38330 lacs for the quarter ending on 30-SEP-2009. Net Profit / (Loss) of Rs. (6786) lacs for the quarter ending on 30-SEP-2010 against Rs. (5909) lacs for the quarter ending on 30-SEP-2009.1 Nov · Board meeting
Inter alia, to consider and approve the unaudited financial results of the Company for the quarter and half year ended September 30, 2010.
Oct 2010
15 Oct · Updates
Wockhardt France and some of its subsidiaries have been placed under safeguard proceedings by the pro-active initiative of the Company. Wockhardt France (Holdings) S.A.S is a subsidiary of Wockhardt EU Operations (Swiss) AG. Wockhardt France is solvent and the safeguard helps the Company to reorganize its business to be viable. Earlier the Company lost the protection of patent of Diacerin through court challenge. The Company, has developed, in the meantime, a successor with a new technology from the Research and Development efforts in India which is undergoing clinical trial in France with over 500 patients. The submission will be filed by first quarter 2011, and the product is likely to be marketed in the first semester of 2012, based on the clinical trial outcome
Sep 2010
21 Sep · Meeting
Annual General Meeting of the Company was duly held on September 20, 2010 and the following resolutions were passed unanimously at the meeting by the members of the Company: (1) Adoption of Audited Balance Sheet as at March 31, 2010, Profit and Loss Account of the fifteen months period ended on that date and the Reports of the Board of Directors and Auditors thereon. (2) Re-appointment of Mr. Aman Mehta as a Director of the Company. (3) Re-appointment of Mr.Bharat Patel as a Director of the Company. (4) Appointment of M/s. Haribhakti & Co., Chartered Accountants as the Statutory Auditors of the Company to hold office from the conclusion of this meeting till the conclusion of next Annual General Meeting of the Company. (5) Re-appointment of Mr. H. F. Khorakiwala as Chairman of the Company, for a period of 5 (five) years with effect from March 01, 2010 and payment of remuneration as provided in the resolution.
Aug 2010
18 Aug · Limited Review Report
Auditors have conducted the limited review for the un-audited financial results for the quarter ended June 30,2010. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.17 Aug · Meeting
Annual General Meeting of the Company will be held September 20, 2010. Further, the Register of Members and Share Transfer Books of the Company will remain closed from September 13, 2010 to September 20, 2010 (both days inclusive) for the purpose of Annual General Meeting.13 Aug · Board meeting
13 Aug · Results
Consolidated Results for the quarter ended on 30-JUN-2010 as follows: Net Sales of Rs. 92164 lacs for quarter ending on 30-JUN-2010 against Rs. 95415 lacs for the quarter ending on 30-JUN-2009. Net Profit / (Loss) of Rs. (11628) lacs for the quarter ending on 30-JUN-2010 against Rs. (18987) lacs for the quarter ending on 30-JUN-2009.13 Aug · Results
Standalone Results for the quarter ended on 30-JUN-2010 as follows: Net Sales of Rs. 39977 lacs for quarter ending on 30-JUN-2010 against Rs. 36673 lacs for the quarter ending on 30-JUN-2009. Net Profit / (Loss) of Rs. (16314) lacs for the quarter ending on 30-JUN-2010 against Rs. (26059) lacs for the quarter ending on 30-JUN-2009.
Jul 2010
30 Jul · Board meeting
Inter alia, to consider and approve the unaudited financial results of the Company for the quarter ended June 30, 2010.
May 2010
20 May · Results
Standalone Results for the period ended on 31-MAR-2010 as follows: Net Sales of Rs. 186851 lacs for period ending on 31-MAR-2010. Net Profit / (Loss) of Rs. (79421) lacs for the period ending on 31-MAR-2010.20 May · Results
Consolidated Results for the period ended on 31-MAR-2010 as follows: Net Sales of Rs. 450142 lacs for period ending on 31-MAR-2010. Net Profit / (Loss) of Rs. (100065) lacs for the period ending on 31-MAR-2010.20 May · Results
Standalone Results for the period ended on 31-MAR-2010 as follows: Net Sales of Rs. 38203 lacs for period ending on 31-MAR-2010. Net Profit / (Loss) of Rs. (29426) lacs for the period ending on 31-MAR-2010.20 May · Results
Consolidated Results for the period ended on 31-MAR-2010 as follows: Net Sales of Rs. 87198 lacs for period ending on 31-MAR-2010. Net Profit / (Loss) of Rs. (56510) lacs for the period ending on 31-MAR-2010.